Analyst Ratings for Marinus Pharma
Portfolio Pulse from Benzinga Insights
Marinus Pharma (NASDAQ:MRNS) has received mostly bullish ratings from analysts in the last quarter, with a total of 8 bullish and somewhat bullish ratings, and 1 indifferent rating. The company has an average price target of $22.44, representing a 11.41% decrease from the previous average price target of $25.33.
September 20, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharma has received mostly bullish ratings from analysts, indicating a positive outlook for the stock. However, the average price target has decreased by 11.41%.
The bullish ratings indicate that analysts have a positive outlook for Marinus Pharma. However, the decrease in the average price target suggests that they expect the stock price to be lower than previously anticipated.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100